+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study



Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study



Neuro-Oncology 14(11): 1404-1412



A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in cases of pediatric recurrent ependymoma (EPN) to estimate sustained objective response rate and progression-free survival (PFS). Eligible patients received 2 doses of single-agent BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ + CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included diffusion-weighted and T1 dynamic contrast enhanced permeability imaging and tumor immunohistochemistry for vascular endothelial growth factor (VEGF)-A and -B, hypoxia inducible factor-2α, VEGF receptor (R)-2, and carbonic anhydrase (CA)-9. Thirteen evaluable patients received a median of 3 courses (range, 2-12) of BVZ + CPT-11. No sustained response was observed in any patient. Median time to progression in 10 patients was 2.2 months (range, 1.9-6.3). Two patients had stable disease for 10 months and 12 months, respectively. Six-month PFS was 25.7% (SE = 11.1%). Grades I-III toxicities related to BVZ treatment included fatigue in 4 patients, systemic hypertension in 2, epistaxis in 1, headache in 1, and avascular necrosis of bone in 1. Although there was a decrease in the mean diffusion ratio following 2 doses of BVZ, it did not correlate with PFS. BVZ + CPT-11 was well tolerated but had minimal efficacy in cases of recurrent EPN.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036628260

Download citation: RISBibTeXText

PMID: 23019233

DOI: 10.1093/neuonc/nos213


Related references

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. Journal of Clinical Oncology 28(18): 3069-3075, 2010

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro-Oncology 16(2): 310-317, 2014

Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 119(23): 4180-4187, 2014

Hgg-39. Effect Of Tumor Treating Fields In Children With Recurrent Or Progressive High-Grade Glioma And Ependymoma (Pediatric Brain Tumor Consortium Pbtc048). Neuro-Oncology 20(Suppl_2): i97, 2018

Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma. Pediatrics International 57(1): 169-171, 2016

Ept-06Outcomes For Patients With Recurrent Medulloblastoma Or Ependymoma Enrolled On Phase Ii Clinical Trials: An Analysis Of Contemporary Children'S Oncology Group (Cog) And Pediatric Brain Tumor Consortium (Pbtc) Trials. Neuro-Oncology 18(Suppl 3): iii25.1-iii25, 2016

Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Journal of Clinical Oncology 29(3): 324-329, 2011

Tmod-20. The Pediatric Brain Tumor Atlas: An Initiative By The ChildrenS Brain Tumor Tissue Consortium And Pacific Pediatric Neurooncology Consortium. Neuro-Oncology 21(Suppl._2): ii125, 2019

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology 19(8): 1135-1144, 2017

A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). Journal of Clinical Oncology 28(18_Suppl): Cra9501-Cra9501, 2016

Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology 18(9): 1319-1325, 2017

Dipg-22. A Phase 1 Trial Of The Histone Deacetylase Inhibitor Panobinostat In Pediatric Patients With Recurrent Or Refractory Diffuse Intrinsic Pontine Glioma: A Pediatric Brain Tumor Consortium (Pbtc) Study. Neuro-Oncology 20(Suppl_2): i53, 2018

EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. Cancer 121(9): 1499-1507, 2015

Ltbk-01. Updates On The Phase Ii And Re-Treatment Study Of Azd6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (Pbtc) Study. Neuro-Oncology 20(Suppl_2): i214, 2018

Cran-21. Phase Ii Study Of Peginterferon Alfa-2b (Pegintron)/Sylatron For Pediatric Patients With Progressive Or Recurrent Craniopharyngioma Following Radiotherapy: A Pediatric Brain Tumor Consortium Study (Pbtc-039). Neuro-Oncology 20(Suppl_2): i40-i41, 2018